0
ARTICLE |

The Use of Prostate-Specific Antigen in Staging Patients With Newly Diagnosed Prostate Cancer FREE

Joseph E. Oesterling, MD; Sandra K. Martin, RN; Erik J. Bergstralh, MS; Franklin C. Lowe, MD, MPH
[+] Author Affiliations

Reprint requests to Department of Urology, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (Dr Oesterling).


JAMA. 1993;269(1):57-60. doi:10.1001/jama.1993.03500010067033
Text Size: A A A
Published online

Objective.  —To assess the need for obtaining radionuclide bone scans in the staging evaluation of patients with newly diagnosed, untreated prostate cancer. This determination was made on the basis of presenting prostate-specific antigen (PSA) levels.

Design.  —Retrospective review.

Participants.  —The medical records of 2064 consecutive patients with prostate cancer who were evaluated at the Mayo Clinic in Rochester, Minn, from January 1989 through December 1990 were reviewed. Eight hundred fifty-two patients with newly diagnosed, untreated disease and a serum PSA concentration less than 20.0 μg/L at presentation comprised the study population.

Main Outcome Measure.  —The rate of false-negative results associated with using the serum PSA concentration to predict bone scan findings.

Results.  —Five hundred sixty-one patients had a serum PSA concentration of 10.0 μg/L or less; only three had an abnormal bone scan result, and one had an indeterminate scan result. Of the 467 men whose PSA value was 8.0 μg/L or less (two times the upper limit of the reference range), none had bone scan results that were either abnormal or indeterminate. The rate of false-negative results for an abnormal bone scan result was 0% with a serum PSA value of 8.0 μg/L or less and 0.5% with a cutoff level of 10.0 μg/L. The 95% upper confidence limit for the rate of false-negative results for all PSA cutoff levels less than 20.0 μg/L was less than 2%.

Conclusions.  —For patients with newly diagnosed, untreated prostate cancer, a serum PSA concentration of 10.0 μg/L or less, and no skeletal symptoms, a staging radionuclide bone scan does not appear to be necessary. This clinical situation applies to 39% of all patients presenting with newly diagnosed prostate cancer. Since more than 130 000 new cases are diagnosed each year, approximately 50 000 patients are affected annually. If the $600 staging bone scan were eliminated for these patients, a significant economic savings to the health care system in this country would be effected.(JAMA. 1993;269:57-60)

REFERENCES

McGregor B, Tulloch AGS, Quinlan MF, Lovegrove F.  The role of bone scanning in the assessment of prostatic carcinoma. Br J Urol . 1978;;50: 178-181.
O'Donoghue EPN, Constable AR, Sherwood T, Stevenson JJ, Chisholm GD.  Bone scanning and plasma phosphatases in carcinoma of the prostate. Br J Urol . 1978;;50:172-177.
Schaffer DL, Pendergrass HP.  Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology . 1976;;121:431-434.
Merrick MV, Ding CL, Chisholm GD, Elton RA.  Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate. Br J Urol . 1985;;57:715-720.
Paulson DF.  Surgical therapy for cancer of the prostate.  In: Skinner DG, Lieskovsky G, eds. Diagnosis and Management of Genitourinary Cancer . Philadelphia, Pa: WB Saunders Co; 1988;:417-424.
Catalona WJ. Prostate Cancer . Orlando, Fla: Grune & Stratton; 1984;.
Oesterling JE.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol . 1991;;145: 907-923.
Chybowski FM, Larson Keller JJ, Bergstralh EJ, Oesterling JE.  Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol . 1991;;145:313-318.
Rock RC, Chan DW, Bruzek D, Waldron C, Oesterling JE, Walsh PC.  Evaluation of monoclonal immunoradiometric assay for prostate-specific antigen. Clin Chem . 1987;;33:2257-2261.
Utz DC, Farrow GM.  Pathologic differentiation and prognosis of prostatic carcinoma. JAMA . 1969;; 209:1701-1703.
American Cancer Society. Cancer Facts and Figures, 1992 . Atlanta, Ga: American Cancer Society; 1992;.
Lindner A, Dekernion JB.  Cost-effective analysis of pre-cystectomy radioisotope scans. J Urol . 1982;;128:1181-1182.
Rosen PR, Murphy KG.  Bone scintigraphy in the initial staging of patients with renal-cell carcinoma: concise communication. J Nucl Med . 1984;; 25:289-291.
Berger GL, Sadlowski RW, Sharpe JR, Finney RP.  Lack of value of routine preoperative bone and liver scans in cystectomy candidates. J Urol . 1981;; 125:637-639.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

McGregor B, Tulloch AGS, Quinlan MF, Lovegrove F.  The role of bone scanning in the assessment of prostatic carcinoma. Br J Urol . 1978;;50: 178-181.
O'Donoghue EPN, Constable AR, Sherwood T, Stevenson JJ, Chisholm GD.  Bone scanning and plasma phosphatases in carcinoma of the prostate. Br J Urol . 1978;;50:172-177.
Schaffer DL, Pendergrass HP.  Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology . 1976;;121:431-434.
Merrick MV, Ding CL, Chisholm GD, Elton RA.  Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate. Br J Urol . 1985;;57:715-720.
Paulson DF.  Surgical therapy for cancer of the prostate.  In: Skinner DG, Lieskovsky G, eds. Diagnosis and Management of Genitourinary Cancer . Philadelphia, Pa: WB Saunders Co; 1988;:417-424.
Catalona WJ. Prostate Cancer . Orlando, Fla: Grune & Stratton; 1984;.
Oesterling JE.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol . 1991;;145: 907-923.
Chybowski FM, Larson Keller JJ, Bergstralh EJ, Oesterling JE.  Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol . 1991;;145:313-318.
Rock RC, Chan DW, Bruzek D, Waldron C, Oesterling JE, Walsh PC.  Evaluation of monoclonal immunoradiometric assay for prostate-specific antigen. Clin Chem . 1987;;33:2257-2261.
Utz DC, Farrow GM.  Pathologic differentiation and prognosis of prostatic carcinoma. JAMA . 1969;; 209:1701-1703.
American Cancer Society. Cancer Facts and Figures, 1992 . Atlanta, Ga: American Cancer Society; 1992;.
Lindner A, Dekernion JB.  Cost-effective analysis of pre-cystectomy radioisotope scans. J Urol . 1982;;128:1181-1182.
Rosen PR, Murphy KG.  Bone scintigraphy in the initial staging of patients with renal-cell carcinoma: concise communication. J Nucl Med . 1984;; 25:289-291.
Berger GL, Sadlowski RW, Sharpe JR, Finney RP.  Lack of value of routine preoperative bone and liver scans in cystectomy candidates. J Urol . 1981;; 125:637-639.
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.